Quick Update: Longevity News, Events, and Jobs.

Decibel Therapeutics IPO. Cambrian exits stealth. Methuselah Fund x Clubhouse.

In this (abbreviated) edition of Longevity Marketcap Telemetry

  1. Last Week in Longevity

  2. Longevity Futures

  3. Longevity Jobs

  4. Long-form research coming soon….

Disclaimer: None of this should be taken as financial advice. This information is for educational purposes only. 

Nathan Cheng // @realNathanCheng // LongevityList.com // LongevityMarketcap.com //BiohackStack.com


***Special Note: I was asked by some of the folks at the NIA to share this grant funding opportunity for organizations looking to conduct clinical trials for therapies in age-related disease:

Early-Phase Clinical Trials of Novel Interventions to Prevent, Delay, or Treat Aging-Related Conditions by Targeting Aging-Related Mechanisms (U01 Clinical Trial Required)

Deadline is March 3rd, 2021. 


Last Week in Longevity

  • Decibel Therapeutics (NASDAQ:DBTX) IPO. This preclinical-stage hearing loss gene therapy company backed by The Longevity Fund, BlackRock, and others announced their IPO filing on Monday last week and began trading on Friday, raising $127 million at $18 per share. Decibel is developing therapies for genetic, chemotherapy-induced, and age-related hearing loss. Note: Frequency Therapeutics (NASDAQ:FREQ) is in Phase 2 for their age-related hearing loss regenerative therapy — I have a small position in both companies.

  • Cellvie raises $5M seed round. Cellvie is a Harvard spinout company that develops autologous mitochondrial transfer therapy in order to treat ischemia-reperfusion injury (damage to oxygen-deprived tissue during blood resupply, typically during heart attack, stroke, organ transplant, etc). The seed round was led by Kizoo Technology Capital, Michael Greve’s VC firm.

  • Cambrian Biopharma comes out of stealth after $60M raise. This portfolio-approach anti-aging biotech company founded by James Peyer (formerly at Apollo Health Ventures) and Christian Angemayer has already brought one of its oncology companies public recently -- Sensei BioTherapeutics (NASDAQ:SNSE). Investors in Cambrian include Mike Novogratz’s Galaxy Digital -- yet another longevity x crypto crossover.   

  • Longeveron (NASDAQ:LGVN) goes public. The Miami-based mesenchymal stem cell company founded by Joshua Hare (University of Miami) raised $26.6M at $10 per share and began trading on February 12th. The stock is presently down 25%.

  • Reason’s Top Longevity Startup Ideas. Reason, the author of the Fight Aging! blog and founder of Repair Biotechnologies wrote an article on the underserved areas of the longevity biotech industry ripe for new startups to tackle. These areas include gut microbiome, gene therapy platforms, bringing longevity interventions to consumers at a scale, revascularization with stem cells, platforms for removing metabolic waste, and rejuvenating hematopoietic (blood-forming) function.

  • Biophytis lists on NASDAQ (BPTS). The French clinical-stage developer of plant-compound mimetics to treat sarcopenia and Duchenne muscular dystrophy announced the listing of depository shares on the NASDAQ on February 10th. They also have a COVID trial in the pipeline (who doesn’t?).


Looking for jobs, companies, or investors in the longevity biotechnology industry? Check out my other website LongevityList.com.


Longevity Futures


Enjoying this content? Want to learn more about investing in longevity biotechnology? Subscribe to the Longevity Marketcap newsletter. It’s free.


Longevity Jobs

Who’s hiring in the longevity industry? Find more longevity jobs on Longevitylist.com


Note: This week’s long-form research content will be emailed separately. I just wanted to get some of the time-sensitive updates (events, grant application notice) out immediately. I anticipate future long form pieces will be much shorter once I get the present (and very large) topic out of the way.

-Nathan

1

How fitting.